{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:27Z","timestamp":1786988067990,"version":"build-2736575974"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejmech.2022.114416","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T11:33:47Z","timestamp":1650972827000},"page":"114416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Similarities and differences between embryonic implantation and CTC invasion: Exploring the roles of abortifacients in cancer metastasis chemoprevention"],"prefix":"10.1016","volume":"237","author":[{"given":"Chunlian","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanzhang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6839-5545","authenticated-orcid":false,"given":"Lee","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejmech.2022.114416_bib1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0039-128X(84)80033-1","article-title":"Synthesis of ent-17-(prop-1-ynyl-17 beta-hydroxy-11 beta-(4-(N,N-dimethylamino)-phenyl)-4,9-estradien-3-one, the antipode of RU-38 486","volume":"44","author":"Ottow","year":"1984","journal-title":"Steroids"},{"key":"10.1016\/j.ejmech.2022.114416_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev.med.48.1.129","article-title":"RU486 (mifepristone): mechanisms of action and clinical uses","volume":"48","author":"Cadepond","year":"1997","journal-title":"Annu. Rev. Med."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114416_bib3","first-page":"1244","article-title":"Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function","volume":"7","author":"Vegeto","year":"1993","journal-title":"Mol. Endocrinol."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114416_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1210\/endrev\/bnaa012","article-title":"Selective progesterone receptor modulators-mechanisms and therapeutic utility","volume":"41","author":"Islam","year":"2020","journal-title":"Endocr. Rev."},{"issue":"14","key":"10.1016\/j.ejmech.2022.114416_bib5","first-page":"3868","article-title":"New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP","volume":"54","author":"Sartorius","year":"1994","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114416_bib6","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/med.21311","article-title":"The unique pharmacological characteristics of mifepristone (RU486): from terminating pregnancy to preventing cancer metastasis","volume":"34","author":"Chen","year":"2014","journal-title":"Med. Res. Rev."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114416_bib7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0022-4731(87)90083-5","article-title":"Plasma concentrations and receptor binding of RU 486 and its metabolites in humans","volume":"26","author":"Heikinheimo","year":"1987","journal-title":"J. Steroid Biochem."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114416_bib8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1208\/s12248-013-9559-2","article-title":"Synthesis, spectral characterization, and in vitro cellular activities of metapristone, a potential cancer metastatic chemopreventive agent derived from mifepristone (RU486)","volume":"16","author":"Wang","year":"2014","journal-title":"AAPS J."},{"issue":"4924","key":"10.1016\/j.ejmech.2022.114416_bib9","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1126\/science.2781282","article-title":"Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor","volume":"245","author":"Baulieu","year":"1989","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ejmech.2022.114416_bib10","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0022-3565(24)38021-8","article-title":"Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)","volume":"288","author":"He","year":"1999","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"8","key":"10.1016\/j.ejmech.2022.114416_bib11","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2174\/138920007782798207","article-title":"The conduct of drug metabolism studies considered good practice (II): in vitro experiments","volume":"8","author":"Jia","year":"2007","journal-title":"Curr. Drug Metabol."},{"issue":"9","key":"10.1016\/j.ejmech.2022.114416_bib12","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1124\/dmd.30.9.985","article-title":"Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4","volume":"30","author":"Khan","year":"2002","journal-title":"Drug Metabol. Dispos.: Biol. Fate Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114416_bib13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0022-5347(25)00290-3","article-title":"Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man","volume":"241","author":"Kawai","year":"1987","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00280-007-0446-3","article-title":"Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate","volume":"61","author":"Jia","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114416_bib15","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.drudis.2013.11.020","article-title":"Drug enterohepatic circulation and disposition: constituents of systems pharmacokinetics","volume":"19","author":"Gao","year":"2014","journal-title":"Drug Discov. Today"},{"issue":"5","key":"10.1016\/j.ejmech.2022.114416_bib16","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0006-2952(96)00357-7","article-title":"Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes","volume":"52","author":"Jang","year":"1996","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114416_bib17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1210\/jcem-68-2-270","article-title":"Distribution of RU 486 and its demethylated metabolites in humans","volume":"68","author":"Heikinheimo","year":"1989","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"4\u20136","key":"10.1016\/j.ejmech.2022.114416_bib18","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0022-4731(87)90160-9","article-title":"Pharmacokinetics and metabolism of RU 486","volume":"27","author":"Lahteenmaki","year":"1987","journal-title":"J. Steroid Biochem."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114416_bib19","first-page":"1241","article-title":"Determinations of mifepristone and its metabolites and their pharmacokinetics in healthy female Chinese subjects","volume":"46","author":"Teng","year":"2011","journal-title":"Yao xue xue bao = Acta pharmaceutica Sinica."},{"issue":"7749","key":"10.1016\/j.ejmech.2022.114416_bib20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41586-019-1019-4","article-title":"Glucocorticoids promote breast cancer metastasis","volume":"567","author":"Obradovi\u0107","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ejmech.2022.114416_bib21","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1158\/1078-0432.CCR-17-0989","article-title":"The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved antiandrogen therapy","volume":"24","author":"Puhr","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114416_bib22","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4161\/cbt.6.2.3652","article-title":"Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors","volume":"6","author":"Zhang","year":"2007","journal-title":"Cancer Biol. Ther."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114416_bib23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ejmech.2022.114416_bib24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/pros.1108","article-title":"Progesterone receptor expression in human prostate cancer: correlation with tumor progression","volume":"48","author":"Bonkhoff","year":"2001","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.ejmech.2022.114416_bib25","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1210\/me.2006-0304","article-title":"Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways","volume":"21","author":"Carnevale","year":"2007","journal-title":"Mol. Endocrinol."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114416_bib26","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.juro.2012.04.102","article-title":"Mifepristone inhibits GR\u03b2 coupled prostate cancer cell proliferation","volume":"188","author":"Ligr","year":"2012","journal-title":"J. Urol."},{"issue":"7","key":"10.1016\/j.ejmech.2022.114416_bib27","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.21873\/anticanres.13479","article-title":"Therapy aimed to suppress the production of the immunosuppressive protein progesterone induced blocking factor (PIBF) may provide palliation and\/or increased longevity for patients with a variety of different advanced cancers - a review","volume":"39","author":"Check","year":"2019","journal-title":"Anticancer Res."},{"issue":"8","key":"10.1016\/j.ejmech.2022.114416_bib28","first-page":"61","article-title":"The effect of treatment with a progesterone receptor antagonist on death from spontaneous lymphocytic leukemia in AKR\/J mice","volume":"66","author":"Check","year":"2006","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib29","first-page":"119","article-title":"Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer","volume":"30","author":"Check","year":"2010","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2022.114416_bib30","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2016-4876","article-title":"Long-term high quality survival with single agent mifepristone treatment despite advanced lung cancer and advanced renal cell carcinoma-2 case reports","volume":"76","author":"Check","year":"2016","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114416_bib31","first-page":"1","article-title":"Prolonged high-quality life in patients with non-small cell lung cancer treated with mifepristone who advanced despite osimertinib","volume":"3","author":"Check","year":"2020","journal-title":"Cancer Sci. Res."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114416_bib32","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3171\/jns.1991.74.6.0861","article-title":"Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone","volume":"74","author":"Grunberg","year":"1991","journal-title":"J. Neurosurg."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114416_bib33","doi-asserted-by":"crossref","first-page":"698","DOI":"10.4103\/0028-3886.263232","article-title":"The role of mifepristone in the management of meningiomas: a systematic review of literature","volume":"67","author":"Sharma","year":"2019","journal-title":"Neurol. India"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/me.2004-0488","article-title":"The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells","volume":"20","author":"Ma","year":"2006","journal-title":"Mol. Endocrinol."},{"issue":"1\u20133","key":"10.1016\/j.ejmech.2022.114416_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jsbmb.2009.06.004","article-title":"Progestin stimulation of manganese superoxide dismutase and invasive properties in T47D human breast cancer cells","volume":"117","author":"Holley","year":"2009","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114416_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.tcb.2017.11.001","article-title":"RANKL and RANK: from mammalian physiology to cancer treatment","volume":"28","author":"Rao","year":"2018","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejmech.2022.114416_bib37","first-page":"8","volume":"vol. 2020","author":"Medina-Lopes","year":"2020"},{"issue":"5804","key":"10.1016\/j.ejmech.2022.114416_bib38","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1126\/science.1130471","article-title":"Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist","volume":"314","author":"Poole","year":"2006","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib39","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3892\/or.2013.2432","article-title":"RU486, a glucocorticoid receptor antagonist, induces apoptosis in U937 human lymphoma cells through reduction in mitochondrial membrane potential and activation of p38 MAPK","volume":"30","author":"Jang","year":"2013","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.ejmech.2022.114416_bib40","first-page":"743","article-title":"Effects of progesterone and anti-progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3","volume":"15","author":"Fauvet","year":"2006","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114416_bib41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00109-011-0821-8","article-title":"Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2","volume":"90","author":"Min","year":"2012","journal-title":"J. Mol. Med. (Berl.)"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/(SICI)1097-0045(20000401)43:1<31::AID-PROS5>3.0.CO;2-#","article-title":"Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture","volume":"43","author":"El Etreby","year":"2000","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.ejmech.2022.114416_bib43","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/pros.2990260405","article-title":"Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone","volume":"26","author":"Lin","year":"1995","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.ejmech.2022.114416_bib44","first-page":"369","article-title":"Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1","volume":"23","author":"Liang","year":"2003","journal-title":"Int. J. Oncol."},{"issue":"22","key":"10.1016\/j.ejmech.2022.114416_bib45","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1158\/1078-0432.CCR-12-3826","article-title":"Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer","volume":"19","author":"Skor","year":"2013","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-018-0683-z","article-title":"Mifepristone inhibits non-small cell lung carcinoma cellular escape from DNA damaging cisplatin","volume":"18","author":"Kapperman","year":"2018","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejmech.2022.114416_bib47","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.3389\/fonc.2020.581814","article-title":"Mifepristone as a potential therapy to reduce angiogenesis and P-glycoprotein associated with glioblastoma resistance to temozolomide","volume":"10","author":"Llaguno-Munive","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2022.114416_bib48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fonc.2021.606907","article-title":"Mifepristone repurposing in treatment of high-grade gliomas","volume":"11","author":"Llaguno-Munive","year":"2021","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114416_bib49","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/0008-5472.CAN-20-1441","article-title":"Enhanced antitumor immunity via endocrine therapy prevents mammary tumor relapse and increases immune checkpoint blockade sensitivity","volume":"81","author":"Sequeira","year":"2021","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.ejmech.2022.114416_bib50","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3748\/wjg.v10.i12.1726","article-title":"Effects of mifepristone on invasive and metastatic potential of human gastric adenocarcinoma cell line MKN-45 in vitro and in vivo","volume":"10","author":"Li","year":"2004","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114416_bib51","first-page":"355","article-title":"A dual mechanism mediates repression of NF-kappaB activity by glucocorticoids","volume":"12","author":"Wissink","year":"1998","journal-title":"Mol. Endocrinol."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114416_bib52","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0015-0282(01)01705-8","article-title":"Glucocorticoid hormone can suppress apoptosis of rat testicular germ cells induced by testicular ischemia","volume":"75","author":"Yazawa","year":"2001","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.ejmech.2022.114416_bib53","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3389\/fphar.2019.01296","article-title":"RU486 metabolite inhibits CCN1\/Cyr61 secretion by MDA-MB-231-endothelial adhesion","volume":"10","author":"Yu","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114416_bib54","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/gerona\/glaa164","article-title":"Metabolic signatures of life span regulated by mating, sex peptide and mifepristone\/RU486 in female Drosophila melanogaster","volume":"76","author":"Landis","year":"2021","journal-title":"J. Gerontol. Ser. A, Biol. Sci. Med. Sci."},{"issue":"12","key":"10.1016\/j.ejmech.2022.114416_bib55","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.tem.2010.09.001","article-title":"Sex hormone metabolism in lung development and maturation","volume":"21","author":"Seaborn","year":"2010","journal-title":"Trends Endocrinol. Metabol.: TEM (Trends Endocrinol. Metab.)"},{"issue":"12","key":"10.1016\/j.ejmech.2022.114416_bib56","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1210\/jc.2006-1472","article-title":"Induction of surfactant protein A expression by cortisol facilitates prostaglandin synthesis in human chorionic trophoblasts","volume":"91","author":"Sun","year":"2006","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"Pt A","key":"10.1016\/j.ejmech.2022.114416_bib57","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.biocel.2016.11.003","article-title":"Surfactant protein A: a key player in lung homeostasis","volume":"81","author":"Nathan","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114416_bib58","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1210\/mend-5-3-414","article-title":"Posttranscriptional regulation of surfactant protein-A messenger RNA in human fetal lung in vitro by glucocorticoids","volume":"5","author":"Boggaram","year":"1991","journal-title":"Mol. Endocrinol."},{"issue":"8","key":"10.1016\/j.ejmech.2022.114416_bib59","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1002\/mc.22645","article-title":"Abortifacient metapristone (RU486 derivative) interrupts CXCL12\/CXCR4 axis for ovarian metastatic chemoprevention","volume":"56","author":"Zheng","year":"2017","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ejmech.2022.114416_bib60","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.biopha.2017.03.091","article-title":"Metapristone suppresses non-small cell lung cancer proliferation and metastasis via modulating RAS\/RAF\/MEK\/MAPK signaling pathway","volume":"90","author":"Zheng","year":"2017","journal-title":"Biomed. Pharmacother.= Biomed. pharmacotherapie"},{"key":"10.1016\/j.ejmech.2022.114416_bib61","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.biopha.2016.01.017","article-title":"In vitro and in vivo efficacy and safety evaluation of metapristone and mifepristone as cancer metastatic chemopreventive agents","volume":"78","author":"Wang","year":"2016","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114416_bib62","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijgo.2009.11.019","article-title":"Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone","volume":"109","author":"Feng","year":"2010","journal-title":"Int. J. Gynaecol. Obstet.: the official organ of the International Federation of Gynaecology and Obstetrics"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib63","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1479-828X.2008.00931.x","article-title":"Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial","volume":"49","author":"Bagaria","year":"2009","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"issue":"7","key":"10.1016\/j.ejmech.2022.114416_bib64","doi-asserted-by":"crossref","first-page":"e6124","DOI":"10.1097\/MD.0000000000006124","article-title":"Different dosages of mifepristone versus enantone to treat uterine fibroids: a multicenter randomized controlled trial","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.ejmech.2022.114416_bib65","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ygyno.2009.10.071","article-title":"A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study","volume":"116","author":"Rocereto","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114416_bib66","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejogrb.2009.06.004","article-title":"Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata","volume":"146","author":"Eisinger","year":"2009","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"9","key":"10.1016\/j.ejmech.2022.114416_bib67","first-page":"1867","article-title":"Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma","volume":"115","author":"Ramondetta","year":"2009","journal-title":"Cancer- Am. Cancer Soc."},{"issue":"4","key":"10.1016\/j.ejmech.2022.114416_bib68","first-page":"455","article-title":"The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial","volume":"74","author":"Romieu","year":"1987","journal-title":"Bull. Cancer"},{"issue":"10\u201311","key":"10.1016\/j.ejmech.2022.114416_bib69","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0039-128X(00)00195-1","article-title":"Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer","volume":"65","author":"Klijn","year":"2000","journal-title":"Steroids"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib70","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0015-0282(16)58022-4","article-title":"Treatment of endometriosis with the antiprogesterone mifepristone (RU486)","volume":"65","author":"Kettel","year":"1996","journal-title":"Fertil. Steril."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114416_bib71","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0002-9378(98)70316-3","article-title":"Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486)","volume":"178","author":"Kettel","year":"1998","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib72","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0015-0282(16)57678-X","article-title":"Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect","volume":"64","author":"Murphy","year":"1995","journal-title":"Fertil. Steril."},{"issue":"8","key":"10.1016\/j.ejmech.2022.114416_bib73","first-page":"3568","article-title":"Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486)","volume":"86","author":"Chu","year":"2001","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114416_bib74","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1210\/jc.2014-1843","article-title":"Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone","volume":"99","author":"Fleseriu","year":"2014","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"9","key":"10.1016\/j.ejmech.2022.114416_bib75","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/sj.eye.6701370","article-title":"Mifepristone treatment in patients with surgically incurable sphenoid-ridge meningioma: a long-term follow-up","volume":"18","author":"de Keizer","year":"2004","journal-title":"Eye"},{"issue":"8","key":"10.1016\/j.ejmech.2022.114416_bib76","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/07357900601062339","article-title":"Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma","volume":"24","author":"Grunberg","year":"2006","journal-title":"Cancer Invest."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114416_bib77","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00701-014-2188-4","article-title":"Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486)","volume":"156","author":"Touat","year":"2014","journal-title":"Acta Neurochir."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114416_bib78","first-page":"1611","article-title":"Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - case report","volume":"29","author":"Check","year":"2009","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114416_bib79","first-page":"623","article-title":"Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types","volume":"30","author":"Check","year":"2010","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.ejmech.2022.114416_bib80","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.21873\/anticanres.13301","article-title":"Mifepristone extends both length and quality of life in a patient with advanced non-small cell lung cancer that has progressed despite chemotherapy and a Check-point inhibitor","volume":"39","author":"Check","year":"2019","journal-title":"Anticancer Res."},{"issue":"18","key":"10.1016\/j.ejmech.2022.114416_bib81","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1056\/NEJM199804303381801","article-title":"Early pregnancy termination with mifepristone and misoprostol in the United States","volume":"338","author":"Spitz","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114416_bib82","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1479-828X.2005.00483.x","article-title":"Comparison of three single doses of mifepristone as emergency contraception: a randomised controlled trial","volume":"45","author":"Jin","year":"2005","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"issue":"23","key":"10.1016\/j.ejmech.2022.114416_bib83","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa1715726","article-title":"Mifepristone pretreatment for the medical management of early pregnancy loss","volume":"378","author":"Schreiber","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2022.114416_bib84","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ajog.2020.04.006","article-title":"Management of early pregnancy loss with mifepristone and misoprostol: clinical predictors of treatment success from a randomized trial","volume":"223","author":"Sonalkar","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114416_bib85","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.contraception.2019.05.006","article-title":"Medical abortion with mifepristone and vaginal misoprostol between 64 and 70days' gestation","volume":"100","author":"Hsia","year":"2019","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.ejmech.2022.114416_bib86","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.contraception.2020.01.009","article-title":"A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation","volume":"101","author":"Dzuba","year":"2020","journal-title":"Contraception"},{"key":"10.1016\/j.ejmech.2022.114416_bib87","doi-asserted-by":"crossref","first-page":"j2011","DOI":"10.1136\/bmj.j2011","article-title":"Self reported outcomes and adverse events after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland","volume":"357","author":"Aiken","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.ejmech.2022.114416_bib88","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0010-7824(03)00171-9","article-title":"Pharmacological properties of mifepristone: toxicology and safety in animal and human studies","volume":"68","author":"Sitruk-Ware","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.ejmech.2022.114416_bib89","first-page":"628","article-title":"Clinical and biological effects of mifepristone treatment for psychotic depression","volume":"vol. 31","author":"Flores","year":"2006"},{"issue":"7","key":"10.1016\/j.ejmech.2022.114416_bib90","first-page":"563","article-title":"Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression","volume":"8","author":"Nihalani","year":"2007","journal-title":"Curr. Opin. Invest. Drugs"},{"issue":"4","key":"10.1016\/j.ejmech.2022.114416_bib91","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10571-018-0614-5","article-title":"Resetting the stress system with a mifepristone challenge","volume":"39","author":"Dalm","year":"2019","journal-title":"Cell. Mol. Neurobiol."},{"issue":"4","key":"10.1016\/j.ejmech.2022.114416_bib92","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/JCP.0b013e3182239191","article-title":"Efficacy and safety of mifepristone for the treatment of psychotic depression","volume":"31","author":"Blasey","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib93","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.biopsych.2018.01.008","article-title":"Combined analysis of mifepristone for psychotic depression: plasma levels associated with clinical response","volume":"84","author":"Block","year":"2018","journal-title":"Biol. Psychiatr."},{"issue":"8","key":"10.1016\/j.ejmech.2022.114416_bib94","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1093\/humrep\/del141","article-title":"Mifepristone-induced nitric oxide release and expression of nitric oxide synthases in the human cervix during early pregnancy","volume":"21","author":"Vaisanen-Tommiska","year":"2006","journal-title":"Hum. Reprod."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114416_bib95","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.ajog.2005.11.026","article-title":"Mifepristone-induced cervical ripening: structural, biomechanical, and molecular events","volume":"194","author":"Clark","year":"2006","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114416_bib96","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0010-7824(93)90004-Q","article-title":"Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women","volume":"48","author":"Shi","year":"1993","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib97","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.fct.2007.07.017","article-title":"Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption","volume":"46","author":"Jia","year":"2008","journal-title":"Food Chem. Toxicol. : an international journal published for the British Industrial Biological Research Association"},{"issue":"5","key":"10.1016\/j.ejmech.2022.114416_bib98","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/oxfordjournals.humrep.a136554","article-title":"Metabolism and serum binding of RU 486 in women after various single doses","volume":"2","author":"Heikinheimo","year":"1987","journal-title":"Hum. Reprod."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib99","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/07853899309147861","article-title":"Dose-response relationships of RU 486","volume":"25","author":"Heikinheimo","year":"1993","journal-title":"Ann. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114416_bib100","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.fertnstert.2005.05.056","article-title":"Management of patients receiving long-term treatment with mifepristone","volume":"84","author":"Spitz","year":"2005","journal-title":"Fertil. Steril."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114416_bib101","first-page":"243","volume":"101","author":"Eisinger","year":"2003","journal-title":"Low-dose mifepristone for uterine leiomyomata"},{"key":"10.1016\/j.ejmech.2022.114416_bib102","doi-asserted-by":"crossref","first-page":"c927","DOI":"10.1136\/bmj.c927","article-title":"Mortality among contraceptive pill users: cohort evidence from Royal College of general practitioners' oral contraception study","volume":"340","author":"Hannaford","year":"2010","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ejmech.2022.114416_bib103","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jamaoncol.2017.4942","article-title":"Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers","volume":"4","author":"Michels","year":"2018","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.ejmech.2022.114416_bib104","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(15)00212-0","article-title":"Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies","volume":"16","author":"Collaborative Group on Epidemiological Studies on Endometrial","year":"2015","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.ejmech.2022.114416_bib105","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1158\/1078-0432.CCR-07-0164","article-title":"Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo","volume":"13","author":"Goyeneche","year":"2007","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib106","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.fertnstert.2005.01.126","article-title":"Effect of mifepristone on proliferation and apoptosis of Ishikawa endometrial adenocarcinoma cells","volume":"84","author":"Li","year":"2005","journal-title":"Fertil. Steril."},{"issue":"5969","key":"10.1016\/j.ejmech.2022.114416_bib107","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1126\/science.327.5969.1072","article-title":"Cancer's circulation problem","volume":"327","author":"Kaiser","year":"2010","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib108","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ccell.2019.12.004","article-title":"Cancer genome evolutionary trajectories in metastasis","volume":"37","author":"Birkbak","year":"2020","journal-title":"Cancer Cell"},{"issue":"25","key":"10.1016\/j.ejmech.2022.114416_bib109","doi-asserted-by":"crossref","first-page":"25ra3","DOI":"10.1126\/scitranslmed.3000403","article-title":"Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer","volume":"2","author":"Stott","year":"2010","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.ejmech.2022.114416_bib110","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nbt.2282","article-title":"Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells","volume":"30","author":"Ramskold","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2022.114416_bib111","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fphar.2020.00135","article-title":"Single cell transcriptome in colorectal cancer-current updates on its application in metastasis, Chemoresistance and the roles of circulating tumor cells","volume":"11","author":"Tieng","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"7173","key":"10.1016\/j.ejmech.2022.114416_bib112","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/nature06385","article-title":"Isolation of rare circulating tumour cells in cancer patients by microchip technology","volume":"450","author":"Nagrath","year":"2007","journal-title":"Nature"},{"issue":"29","key":"10.1016\/j.ejmech.2022.114416_bib113","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1200\/JCO.2006.10.4323","article-title":"End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group","volume":"25","author":"Sargent","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114416_bib114","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1245\/s10434-020-08827-6","article-title":"Prognostic significance of circulating tumor cells with mesenchymal phenotypes in patients with gastric cancer: a prospective study","volume":"28","author":"Ishiguro","year":"2021","journal-title":"Ann. Surg Oncol."},{"issue":"9","key":"10.1016\/j.ejmech.2022.114416_bib115","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","article-title":"Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 randomized clinical trial","volume":"6","author":"Radovich","year":"2020","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41368-020-00087-0","article-title":"Radiotherapy targeting cancer stem cells \u201cawakens\u201d them to induce tumour relapse and metastasis in oral cancer","volume":"12","author":"Liu","year":"2020","journal-title":"Int. J. Oral Sci."},{"key":"10.1016\/j.ejmech.2022.114416_bib117","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/bs.acr.2018.12.002","article-title":"Dormancy and cancer stem cells: an enigma for cancer therapeutic targeting","volume":"141","author":"Talukdar","year":"2019","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114416_bib118","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.semcancer.2021.02.002","article-title":"Tackling cancer cell dormancy: insights from immune models, and transplantation","volume":"78","author":"Corthay","year":"2021","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114416_bib119","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0002-9440(10)65628-3","article-title":"Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases","volume":"153","author":"Luzzi","year":"1998","journal-title":"Am. J. Pathol."},{"issue":"6151","key":"10.1016\/j.ejmech.2022.114416_bib120","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1126\/science.1235226","article-title":"Circulating tumor cells","volume":"341","author":"Plaks","year":"2013","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib121","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1158\/2159-8290.CD-19-0384","article-title":"Circulating tumor cells exhibit metastatic tropism and reveal brain metastasis drivers","volume":"10","author":"Klotz","year":"2020","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114416_bib122","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10585-007-9130-6","article-title":"The tumor cell-host organ interface in the early onset of metastatic organ colonisation","volume":"25","author":"Gassmann","year":"2008","journal-title":"Clin. Exp. Metastasis"},{"issue":"3","key":"10.1016\/j.ejmech.2022.114416_bib123","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/sj.bjc.6605491","article-title":"Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype","volume":"102","author":"Ameri","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.ejmech.2022.114416_bib124","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1083\/jcb.124.4.619","article-title":"Disruption of epithelial cell-matrix interactions induces apoptosis","volume":"124","author":"Frisch","year":"1994","journal-title":"J. Cell Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114416_bib125","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/path.3000","article-title":"Anoikis: an emerging hallmark in health and diseases","volume":"226","author":"Taddei","year":"2012","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114416_bib126","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-2007-1016235","article-title":"Embryo implantation and tumor metastasis: common pathways of invasion and angiogenesis","volume":"17","author":"Murray","year":"1999","journal-title":"Semin. Reprod. Endocrinol."},{"issue":"7","key":"10.1016\/j.ejmech.2022.114416_bib127","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1042\/CS20090503","article-title":"Regulation of invasive growth: similar epigenetic mechanisms underpin tumour progression and implantation in human pregnancy","volume":"118","author":"Perry","year":"1979","journal-title":"Clin. Sci. (London, England"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1242\/jcs.175943","article-title":"Embryo-epithelium interactions during implantation at a glance","volume":"130","author":"Aplin","year":"2017","journal-title":"J. Cell Sci."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2022.114416_bib129","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0165-0378(98)00021-7","article-title":"Functional regulation of human trophoblast differentiation","volume":"39","author":"Morrish","year":"1998","journal-title":"J. Reprod. Immunol."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114416_bib130","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1210\/en.2017-03082","article-title":"Embryo implantation: war in times of love","volume":"159","author":"Ashary","year":"2018","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib131","first-page":"1","article-title":"Embedding similarities between embryos and circulating tumor cells: fundamentals of abortifacients used for cancer metastasis chemoprevention","volume":"40","author":"Wang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res. : CR (Clim. Res.)"},{"issue":"33","key":"10.1016\/j.ejmech.2022.114416_bib132","doi-asserted-by":"crossref","first-page":"24120","DOI":"10.1074\/jbc.M611435200","article-title":"Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival. Evidence for inside-out signaling leading to anoikis","volume":"282","author":"Plotkin","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2022.114416_bib133","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1002\/jcp.27149","article-title":"Shear stress promotes anoikis resistance of cancer cells via caveolin-1-dependent extrinsic and intrinsic apoptotic pathways","volume":"234","author":"Li","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"7","key":"10.1016\/j.ejmech.2022.114416_bib134","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1074\/jbc.M111.286138","article-title":"Studies using an in vitro model show evidence of involvement of epithelial-mesenchymal transition of human endometrial epithelial cells in human embryo implantation","volume":"287","author":"Uchida","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib135","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/humupd\/dmy035","article-title":"The role of mesenchymal-epithelial transition in endometrial function","volume":"25","author":"Owusu-Akyaw","year":"2019","journal-title":"Hum. Reprod. Update"},{"issue":"6","key":"10.1016\/j.ejmech.2022.114416_bib136","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.devcel.2008.05.009","article-title":"Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis","volume":"14","author":"Yang","year":"2008","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ejmech.2022.114416_bib137","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev-pathol-020117-043854","article-title":"Epithelial mesenchymal transition in tumor metastasis","volume":"13","author":"Mittal","year":"2018","journal-title":"Ann. Rev. Pathol."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114416_bib138","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.tcb.2020.07.003","article-title":"EMT, MET, plasticity, and tumor metastasis","volume":"30","author":"Bakir","year":"2020","journal-title":"Trends Cell Biol."},{"issue":"12","key":"10.1016\/j.ejmech.2022.114416_bib139","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1002\/jcp.25797","article-title":"Epithelial-mesenchymal transition (EMT): a biological process in the development, stem cell differentiation, and tumorigenesis","volume":"232","author":"Chen","year":"2017","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib140","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/71429","article-title":"Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis","volume":"6","author":"Al-Mehdi","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2022.114416_bib141","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3389\/fimmu.2019.02120","article-title":"Altered cell adhesion and glycosylation promote cancer immune suppression and metastasis","volume":"10","author":"Laubli","year":"2019","journal-title":"Front. Immunol."},{"issue":"6050","key":"10.1016\/j.ejmech.2022.114416_bib142","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1126\/science.1207438","article-title":"Human sperm binding is mediated by the sialyl-Lewis(x) oligosaccharide on the zona pellucida","volume":"333","author":"Pang","year":"2011","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ejmech.2022.114416_bib143","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/carcin\/21.3.525","article-title":"Chemoprevention of cancer","volume":"21","author":"Sporn","year":"2000","journal-title":"Carcinogenesis"},{"issue":"5","key":"10.1016\/j.ejmech.2022.114416_bib144","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/carcin\/bgu063","article-title":"The failure of cancer chemoprevention","volume":"35","author":"Potter","year":"2014","journal-title":"Carcinogenesis"},{"issue":"10","key":"10.1016\/j.ejmech.2022.114416_bib145","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrc3125","article-title":"Unravelling the complexity of metastasis - molecular understanding and targeted therapies","volume":"11","author":"Sethi","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.ejmech.2022.114416_bib146","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrc.2016.25","article-title":"Targeting metastasis","volume":"16","author":"Steeg","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.ejmech.2022.114416_bib147","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41571-018-0134-8","article-title":"A framework for the development of effective anti-metastatic agents","volume":"16","author":"Anderson","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.ejmech.2022.114416_bib148","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.2174\/092986709788682146","article-title":"Current evaluation of the millennium phytomedicine--ginseng (I): etymology, pharmacognosy, phytochemistry, market and regulations","volume":"16","author":"Jia","year":"2009","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib149","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00000658-200001000-00003","article-title":"Cell surface molecules and their prognostic values in assessing colorectal carcinomas","volume":"231","author":"Haier","year":"2000","journal-title":"Ann. Surg."},{"issue":"24","key":"10.1016\/j.ejmech.2022.114416_bib150","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/jnci\/djq466","article-title":"Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy?","volume":"102","author":"Meyskens","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114416_bib151","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA A Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114416_bib152","first-page":"363","article-title":"Cancer treatment and survivorship statistics","volume":"69","author":"Miller","year":"2019","journal-title":"CA A Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114416_bib153","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114416_bib154","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJMp2007839","article-title":"Progress in cancer research, prevention, and Care","volume":"383","author":"Schilsky","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ejmech.2022.114416_bib155","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat. Rev. Cancer"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342200318X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342200318X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:45:13Z","timestamp":1759329913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342200318X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":155,"alternative-id":["S022352342200318X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114416","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Similarities and differences between embryonic implantation and CTC invasion: Exploring the roles of abortifacients in cancer metastasis chemoprevention","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114416"}}